Clinical Trial Detail

NCT ID NCT03611738
Title Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

non-small cell lung carcinoma

Therapies

Ceritinib + Docetaxel

Age Groups: adult senior

Additional content available in CKB BOOST